FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767575038> ?p ?o ?g. }

• W2767575038 abstract "Abstract Background Direct acting antivirals ( DAA s) have revolutionized hepatitis C ( HCV ) treatment with >90% cure rates even in real‐world studies, giving hope that HCV can be eliminated. However, for DAA s to have a population‐level impact on the burden of HCV disease, treatment uptake needs to be expanded. We investigated temporal trends in HCV treatment uptake and evaluated factors associated with second‐generation DAA initiation and efficacy among key HIV ‐ HCV co‐infected populations in Canada. Methods The Canadian HIV ‐ HCV Co‐Infection Cohort Study prospectively follows 1699 participants from 18 centres. Among HCV RNA + participants, we determined the incidence of HCV treatment initiation per year overall and by key populations between 2007 and 2015. Key populations were based on World Health Organization ( WHO ) guidelines including: people who actively inject drugs ( PWID ) (reporting injection drug use, last 6 months); Indigenous people; women and men who have sex with men ( MSM ). Multivariate Cox models were used to estimate adjusted hazard ratios ( aHR ) and 2‐year probability of initiating second‐generation DAA s for each of the key populations. Results Overall, HCV treatment initiation rates increased from 8 (95% CI , 6–11) /100 person‐years in 2013 to 28 (95% CI , 23–33) /100 person‐years in 2015. Among 911 HCV RNA + participants, there were 202 second‐generation DAA initiations (93% with interferon‐free regimens). After adjustment ( aHR , 95% CI ), active PWID (0.60, 0.38–0.94 compared to people not injecting drugs) and more generally, people with lower income (<$18 000 CAD /year) (0.50, 0.35, 0.71) were less likely to initiate treatment. Conversely, MSM were more likely to initiate 1.95 (1.33, 2.86) compared to heterosexual men. In our cohort, the population profile with the lowest 2‐year probability of initiating DAA s was Indigenous, women who inject drugs (5%, 95% CI 3–8%). Not having any of these risk factors resulted in a 35% (95% CI 32–38%) probability of initiating DAA treatment. Sustained virologic response ( SVR ) rates were >82% in all key populations. Conclusion While treatment uptake has increased with the availability of second‐generation DAA s, marginalized populations, already engaged in care, are still failing to access treatment. Targeted strategies to address barriers are needed to avoid further health inequities and to maximize the public health impact of DAA s." @default.
• W2767575038 created "2017-11-17" @default.
• W2767575038 creator A5000568574 @default.
• W2767575038 creator A5002632928 @default.
• W2767575038 creator A5009499168 @default.
• W2767575038 creator A5020475843 @default.
• W2767575038 creator A5026415367 @default.
• W2767575038 creator A5032029490 @default.
• W2767575038 creator A5032299448 @default.
• W2767575038 creator A5034437717 @default.
• W2767575038 creator A5048076117 @default.
• W2767575038 creator A5048550846 @default.
• W2767575038 creator A5065648812 @default.
• W2767575038 creator A5066810153 @default.
• W2767575038 creator A5085309738 @default.
• W2767575038 creator A5087124606 @default.
• W2767575038 date "2017-11-01" @default.
• W2767575038 modified "2023-10-17" @default.
• W2767575038 title "Disparities in direct acting antivirals uptake in <scp>HIV</scp>‐hepatitis C co‐infected populations in Canada" @default.
• W2767575038 cites W1574174041 @default.
• W2767575038 cites W1903580466 @default.
• W2767575038 cites W1967228793 @default.
• W2767575038 cites W1968345917 @default.
• W2767575038 cites W1981564509 @default.
• W2767575038 cites W1988756738 @default.
• W2767575038 cites W1989415380 @default.
• W2767575038 cites W1994269097 @default.
• W2767575038 cites W2004206666 @default.
• W2767575038 cites W2010430808 @default.
• W2767575038 cites W2021209081 @default.
• W2767575038 cites W2050214831 @default.
• W2767575038 cites W2062663143 @default.
• W2767575038 cites W2062957362 @default.
• W2767575038 cites W2072462822 @default.
• W2767575038 cites W2089049687 @default.
• W2767575038 cites W2091326103 @default.
• W2767575038 cites W2094488173 @default.
• W2767575038 cites W2098521993 @default.
• W2767575038 cites W2104563699 @default.
• W2767575038 cites W2106777786 @default.
• W2767575038 cites W2113559481 @default.
• W2767575038 cites W2113676816 @default.
• W2767575038 cites W2117027295 @default.
• W2767575038 cites W2118771356 @default.
• W2767575038 cites W2142434090 @default.
• W2767575038 cites W2152282081 @default.
• W2767575038 cites W2160124272 @default.
• W2767575038 cites W2163373419 @default.
• W2767575038 cites W2171484293 @default.
• W2767575038 cites W2328909886 @default.
• W2767575038 cites W2343674560 @default.
• W2767575038 cites W2345039275 @default.
• W2767575038 cites W2345197548 @default.
• W2767575038 cites W2415346488 @default.
• W2767575038 cites W2460461302 @default.
• W2767575038 cites W2460814285 @default.
• W2767575038 cites W2463563063 @default.
• W2767575038 cites W2469966207 @default.
• W2767575038 cites W2510261413 @default.
• W2767575038 cites W2510623134 @default.
• W2767575038 cites W2513148844 @default.
• W2767575038 cites W2516274423 @default.
• W2767575038 cites W2518172340 @default.
• W2767575038 cites W2531749020 @default.
• W2767575038 cites W2560140596 @default.
• W2767575038 cites W2582003424 @default.
• W2767575038 cites W2590576529 @default.
• W2767575038 cites W298905541 @default.
• W2767575038 doi "https://doi.org/10.1002/jia2.25013" @default.
• W2767575038 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5810331" @default.
• W2767575038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29116684" @default.
• W2767575038 hasPublicationYear "2017" @default.
• W2767575038 type Work @default.
• W2767575038 sameAs 2767575038 @default.
• W2767575038 citedByCount "50" @default.
• W2767575038 countsByYear W27675750382018 @default.
• W2767575038 countsByYear W27675750382019 @default.
• W2767575038 countsByYear W27675750382020 @default.
• W2767575038 countsByYear W27675750382021 @default.
• W2767575038 countsByYear W27675750382022 @default.
• W2767575038 countsByYear W27675750382023 @default.
• W2767575038 crossrefType "journal-article" @default.
• W2767575038 hasAuthorship W2767575038A5000568574 @default.
• W2767575038 hasAuthorship W2767575038A5002632928 @default.
• W2767575038 hasAuthorship W2767575038A5009499168 @default.
• W2767575038 hasAuthorship W2767575038A5020475843 @default.
• W2767575038 hasAuthorship W2767575038A5026415367 @default.
• W2767575038 hasAuthorship W2767575038A5032029490 @default.
• W2767575038 hasAuthorship W2767575038A5032299448 @default.
• W2767575038 hasAuthorship W2767575038A5034437717 @default.
• W2767575038 hasAuthorship W2767575038A5048076117 @default.
• W2767575038 hasAuthorship W2767575038A5048550846 @default.
• W2767575038 hasAuthorship W2767575038A5065648812 @default.
• W2767575038 hasAuthorship W2767575038A5066810153 @default.
• W2767575038 hasAuthorship W2767575038A5085309738 @default.
• W2767575038 hasAuthorship W2767575038A5087124606 @default.
• W2767575038 hasBestOaLocation W27675750381 @default.
• W2767575038 hasConcept C120665830 @default.
• W2767575038 hasConcept C121332964 @default.
• W2767575038 hasConcept C126322002 @default.

• next